STADA Arzneimittel Aktiengesellschaft is a global pharmaceutical company specializing in generic medications and consumer healthcare products. Founded in 1895 in Dresden, Germany, the company has built a reputation for providing high-quality, affordable medicines across a broad range of therapeutic areas. STADA’s portfolio encompasses prescription generics, biosimilars, and over-the-counter remedies, addressing common conditions such as pain management, cardiovascular health, and dermatological care.
The company’s generics division develops and manufactures off-patent drugs, allowing healthcare systems and patients to gain access to cost-effective alternatives to branded pharmaceuticals. STADA also markets a diverse selection of consumer healthcare brands, including cold and flu remedies, dietary supplements, and skin protection products. Through continuous investment in research and development, the company ensures that its offerings meet stringent safety and efficacy standards while maintaining competitive pricing.
With operations spanning more than 30 countries, STADA serves markets across Europe, Latin America, the Middle East, and Asia. The company’s manufacturing network comprises state-of-the-art facilities in Germany, France, Italy, and other strategic locations, supporting local and regional supply chains. In addition to its owned plants, STADA collaborates with contract manufacturing organizations to expand production capacity and accelerate time-to-market for new product introductions.
Over the years, STADA has undergone significant transformation, including its acquisition by private equity firms in 2017 and subsequent public relisting. Under the leadership of Chief Executive Officer Peter Goldschmidt, the company is focused on sustainable growth, operational excellence, and the expansion of its specialty portfolio. STADA’s management team emphasizes a culture of innovation and compliance, aiming to deliver long-term value to patients, healthcare partners, and shareholders.
AI Generated. May Contain Errors.
Free STDAF Stock Alerts